NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 14th August 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Dr Alistair Patton Present for all items
3. Dr Andrew Makin Present for all items
4. Dr Daniel Gallacher Present for all items
5. Dr Francis Drobniewski Present for all items
6. Dr Rhiannon Owen Present for all items
7. Dr Stuart Williams Present for all items
8. Dr Veline L’Esperance Present for all items
9. Dr Warren Linley Items 4.1 to 4.2.2
10. Kemi Gibson Items 4.1 to 4.2.2
11. Lisa Attrill Present for all items
12. Nigel Westwood Present for all items
13. Peter Wheatley-Price Present for all items
14. Professor David McAllister Present for all items
15. Tony Wootton Present for all items
16. Vanessa Danielson Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 3.3.2

Jeremy Powell, Project Manager Items 1.1 to 3.3.2

Yelan Guo, Heath Technology Assessment Adviser Items 1.1 to 3.3.2

Luke Cowie, Heath Technology Assessment Analyst Items 1.1 to 3.3.2

Ross Dent, Associate Director Items 4.1 to 4.2.2

Vonda Murray (on behalf of Louise Jafferally), Project Manager

 Items 4.1 to 4.2.2

Harsimran Sarpal, Heath Technology Assessment Adviser Items 4.1 to 4.2.2

Sally Doss, Heath Technology Assessment Analyst Items 4.1 to 4.2.2

External assessment group representatives present

Geoff Frampton, Southampton Health Technology Assessment Centre

 Items 1.1 to 3.2.1

Fay Chinnery, Southampton Health Technology Assessment Centre

 Items 1.1 to 3.2.1

Sarah Davis, School of Health and Related Research Items 4.1 to 4.1.3

Andrew Metry, School of Health and Related Research Items 4.1 to 4.1.3

Clinical, Patient & NHS England experts present

Dr Maria Isabel Leite, Consultant Neurologist, clinical expert, nominated by UCB Pharma

 Items 1.1 to 3.2.1

Dr Jennifer Spillane, Consultant Neurologist, clinical expert, nominated by Association of British Neurologists Items 1.1 to 3. 2.1

Katie Brown, Patient expert, nominated by Myaware Items 1.1 to 3. 2.1

Abuk (Abby) Mabil, Patient expert, nominated by Myaware Items 1.1 to 3. 2.1

James Richardson, NHSE CDF Lead Oncology Pharmacist Items 4.1 to 4.2.2

Professor Tim Somervaille, Professor of Haematological Oncology and Honorary Consultant in Haematology, clinical expert, nominated by BMS

 Items 4.1 to 4.1.3

Professor Beth Psalia, Associate Professor and Consultant Haematologist, clinical expert, nominated by MPN Voice Items 4.1 to 4.1.3

Andy Tattersall, Advocacy Coordinator, MPN Voice, patient expert, nominated by MPN Voice Items 4.1 to 4.1.3

Jon Mathias, Co-Chair, MPN Voice, patient expert, nominated by MPN Voice

 Items 4.1 to 4.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
1. The chair noted apologies from Toby Smith, Natalia Kunst, Gabriel Rogers, Baljit Singh, Anna Pracz, Bushra Hasnie, Mark Tanner and Hatim Abdulhussein.

### News and announcements

* 1. None.
1. **Appraisal of Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from UCB Pharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10994).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by David McAllister (clinical), Peter Wheatley-Price (cost) Nigel Westwood (lay).
	2. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10994>.
1. **Appraisal of Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bristol-Myers Squibb.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11370).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wootton (lay), Vanessa Danielson (cost) and Veline L’Esperance (clinical).
	2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11370>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 11th September and will start promptly at 9am.